Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Issued
Ratios

Ligand Pharmaceuticals (LGNDZ) Cost of Revenue (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Cost of Revenue for 15 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • Quarterly Cost of Revenue rose 5.46% to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.5 million through Dec 2025, up 31.38% year-over-year, with the annual reading at $14.5 million for FY2025, 31.38% up from the prior year.
  • Cost of Revenue hit $3.0 million in Q4 2025 for Ligand Pharmaceuticals, down from $3.8 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $30.6 million in Q2 2021 to a low of $1.6 million in Q4 2023.
  • Historically, Cost of Revenue has averaged $7.6 million across 5 years, with a median of $3.8 million in 2023.
  • Biggest five-year swings in Cost of Revenue: soared 300.22% in 2021 and later plummeted 92.41% in 2023.
  • Year by year, Cost of Revenue stood at $12.0 million in 2021, then skyrocketed by 80.36% to $21.6 million in 2022, then tumbled by 92.41% to $1.6 million in 2023, then surged by 72.88% to $2.8 million in 2024, then grew by 5.46% to $3.0 million in 2025.
  • Business Quant data shows Cost of Revenue for LGNDZ at $3.0 million in Q4 2025, $3.8 million in Q3 2025, and $2.9 million in Q2 2025.